MYC and glioblastoma: Inhibition of IGFBP3, another FAM20C substrate and a downstream effector of the YTHDF2-MYC axis in glioblastoma stem cells (GSCs), decreases GSC viability without affecting NSCs and impairs glioblastoma growth in vivo (68).